Skip Navigation


Annals of Oncology Advance Access originally published online on July 27, 2006
Annals of Oncology 2006 17(11):1644-1649; doi:10.1093/annonc/mdl169
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/11/1644    most recent
mdl169v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Blancas, I
Right arrow Articles by Lluch, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blancas, I
Right arrow Articles by Lluch, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

breast cancer

Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor

I Blancas1,*, JL García-Puche2, B Bermejo1, EO Hanrahan3, C Monteagudo4, A Martínez-Agulló5, R Rouzier6, BT Hennessy3, V Valero3 and A Lluch1

1 Department of Oncology and Hematology, Clinic Hospital, Valencia, Spain
4 Department of Pathology, Clinic Hospital, Valencia, Spain
5 Department of Surgery, Clinic Hospital, Valencia, Spain
2 Unit of Oncology, San Cecilio Clinic Hospital, Granada, Spain
3 Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
6 Department of Gynecology and Obstetrics, Hôpital Tenon, Tenon, France

*Correspondence to: Dr I. Blancas, Unidad de Oncología, Hospital Clínico San Cecilio, Avda. Dr. Oloriz 16 18012 Granada, Spain. Tel: +34-958023479; Fax: +34-958209291; E-mail: isabelblancas{at}hotmail.com

Background: The aim of the study was to determine whether the number of lymph nodes removed at axillary dissection is associated with recurrence and survival in node-negative breast cancer (NNBC) patients.

Patients and methods: We retrospectively reviewed the medical records of 1606 women with pathologically node-negative T1–T3 invasive breast cancer. Median follow-up was 61 months (range 2–251). Potential prognostic factors assessed included: number of axillary lymph nodes examined, age, menopausal status, tumor size, histological type, tumor grade, estrogen receptor(ER), progesterone receptor (PR) and HER2.

Results: At 5 years, relapse-free survival (RFS) rate was 85% and breast cancer-specific survival (BCSS) rate was 94%. In univariate analysis, factors significantly associated with lower RFS and BCSS were: fewer than six lymph nodes examined (RFS, P = 0.01; BCSS, P = 0.007), tumor size >2 cm, grade III, negative ER or PR. Statistically significant factors for lower RFS and BCSS in multivariate analysis were: fewer than six lymph nodes examined [RFS, hazard ratio (HR) 1.36, P = 0.029; BCSS, HR 1.87, P = 0.005], tumor size >2 cm, tumor grade III and negative PR.

Conclusions: Examination of fewer than six lymph nodes is an adverse prognostic factor in NNBC because it could lead to understaging. Six or more nodes need to be examined at axillary dissection to be confident of a node-negative status. This may be useful, in conjunction with other prognostic factors, in the assessment of NNBC patients for adjuvant systemic therapy.

Key words: breast, cancer, lymph, nodes, number, prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
E. O. Hanrahan, A. M. Gonzalez-Angulo, S. H. Giordano, R. Rouzier, K. R. Broglio, G. N. Hortobagyi, and V. Valero
Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma
J. Clin. Oncol., November 1, 2007; 25(31): 4952 - 4960.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.